Legend Biotech recently achieved record quarterly sales and profitability for its CARVYKTI multiple myeloma therapy, enhanced by the removal of FDA REMS restrictions that limited patient monitoring and driving. CARVYKTI’s growing global availability, solid long-term survival data, and manufacturing expansion position it as a major player in CAR-T treatments. While these developments strengthen the investment narrative around Legend, the company remains highly dependent on CARVYKTI, inviting scrutiny over potential risks from market competition and pricing pressures. Projections suggest significant revenue growth by 2029, with some analysts even anticipating higher figures, though the evolving competitive landscape poses ongoing challenges. Overall, investors are advised to consider these factors carefully when evaluating Legend Biotech.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-139-after-carvykti-record-sales-an
